Grace K. Suh, MD

Clinical Associate of Medicine

Grace K. Suh, MD, is a medical oncologist who is dedicated to caring for patients with complex malignancies. Her mission is to provide cancer patients with evidence-based and state-of-the-art treatments while offering compassion and empathy to each patient and his/her family. With that goal in mind, she is focused on bringing the highest level of academic medicine to each individual that she treats, not only to improve their outcomes but also to preserve their quality of life. Her clinical practice encompasses a broad range of cancer patients, where she approaches each patient with a team of doctors to provide multidisciplinary care.

As an accomplished researcher, Dr. Suh has been a principle investigator on several translational research projects. She has collaborated with world-renown cancer researchers and has presented her work at national and international meetings. She has also authored a number of review articles and book chapters on molecular oncology. Her research has been funded through grants from the National Institutes of Health, American Society of Clinical Oncology and the American Association for Cancer Research.

Practice Location

The University of Chicago Medicine
Comprehensive Cancer Center at Silver Cross
1850 Silver Cross Blvd.
New Lenox, IL 60451

Center for Advanced Medicine
5758 S. Maryland Avenue
Chicago, IL 60637

Year Started Practice

2010

Board Certifications

Medical Oncology
Internal Medicine

Medical School

Yale University School of Medicine, New Haven, CT

Internship

Hospital of the University of Pennsylvania

Residency

Yale-New Haven Hospital, New Haven, CT

Fellowship

MD Anderson Cancer Center, Houston

Memberships

American Association for Cancer Research
American College of Physicians
American Society of Clinical Oncology

Languages Spoken

English
Korean

Office Phone

(815) 300-1400

Office Fax

(815) 485-4830

Office Postal Address

Grace K. Suh, MD
The University of Chicago Medicine
Comprehensive Cancer Center at Silver Cross Hospital
1850 Silver Cross Blvd.
New Lenox, IL 60451

Physician Photo

Clinical Interests

Request an appointment online
or call UCM Connect at
1-888-824-0200

Physicians, contact the cancer intake line at (773) 702-8222.

Read More About Dr. Suh

Dr. Suh's practice is based at the University of Chicago Medicine Comprehensive Cancer Center at Silver Cross Hospital.

Selected Publications

Grace K. Suh, Bryan T. Hennessy, Roeland Verhaak, Ji-Yeon Yang, Gordon B. Mills, and Robert C. Bast, Jr. Chapter 54; Molecular Targets for Epithelial Cancer. Molecular Oncology, Causes of Cancer and Targets for Treatment, edited by Edward P. Gelmann, Charles L. Sawyers, Frank J. Rauscher, III. Cambridge University Press.

Suh GK, Younes A. Prognosis and outcomes of lymphocyte-predominant Hodgkin's lymphoma. Nat Clin Pract Oncol. 2008 Aug;5(8):493.

Suh GK, McLaughlin P, Romaguera JE, Hagemeister FB, Pro B, Khouri IF, Samaniego F, Rodriguez MA, Fayad LE, Feng L, Younes A. Long-term follow-up of paclitaxel and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. 10th International Conference on Malignant Lymphoma: Lugano, Switzerland, June, 2008 (abstr 217).

Suh GK. Book Review. Final Exam: A Surgeon’s Reflection on Mortality. J Palliat Med 2007 June;10(3): 815-819.

Suh GK, McLaughlin P, Romaguera JE, Hagemeister FB, Pro B, Khouri IF, Samaniego F, Rodriguez MA, Fayad LE, Feng L, Younes A. Long-term follow-up of paclitaxel and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 26: 2008 (May 20 suppl; abstr 8599).

Suh, GK. Oral presentation. ARHI-induced autophagy is mediated through transcription factor FoxO3a and can be rescued by growth factors. American Society for Cancer Research Annual Meeting, Denver, CO, April 19, 2009.

Badgwell DB, Lu Z, Le K, Gao F, Yang M, Suh GK, Bao JJ, Das P, Andreeff M, Chen W, Yu Y, Ahmed AA, S-L Liao W, Bast RC Jr. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene. 2012 Jan 5;31(1):68-79.